title: [Study of corvitin efficiency in primary glaucoma].
abstract: There were concluded our results of animal experimental investigation and clinical observation of the quercetin-containing preparation corvitin (C) in primary glaucoma treatment. On the model of disease it is shown for rabbit, that introduction of 0.5 ml 2 % C as factious instillation into the eye a basely decreased eye blood flow was increased twice, mionectic at glaucoma eye hydrodynamics was normalized : the outflow of liquid increased on 58 %, inflow - on 52 %, intraocular pressure went down on 14%. Intravenous inflowing of C brought down expressed of oxidative stress - M[see text]A in blood is decreased on 40 %, level of endothelial dysfunction marker NO is increased on 70 %. On the model of glaucoma for rats C, entered protractedly, showed the neuroprotective actions on the neurons of retina, promoting survivability of ganglion cells, that it is shown on histological preparations. Application C in the clinic of glaucoma (intravenously a 0.5 g of preparation in 100 ml of solution) improved for patients a blood supply in the eye on 25 %, and also rendered a positive antioxidant and metabolic effect. Noted positive influences of C concurrently to important pathogeneses factors such as regional eye blood supply, eye hydrodynamics, oxidative stress, metabolic changes, survival of retina neurons grounds to talk about new strategy of pathogenesis therapy of glaucoma.
authors.forename: I M
authors.initials: IM
authors.lastname: Mykheĭtseva
authors.forename: L T
authors.initials: LT
authors.lastname: Kashyntseva
authors.forename: O V
authors.initials: OV
authors.lastname: Artemov
authors.forename: N I
authors.initials: NI
authors.lastname: Khramenko
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D005123:Eye / Q000098:blood supply* / Q000187:drug effects* / Q000473:pathology; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use*; D005901:Glaucoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007275:Injections, Intravenous; D007429:Intraocular Pressure / Q000187:drug effects; D008315:Malondialdehyde / Q000097:blood; D008833:Microcirculation / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D009569:Nitric Oxide / Q000097:blood; D009573:Nitrites / Q000097:blood; D018384:Oxidative Stress / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D014065:Tonometry, Ocular; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D005419:Flavonoids; D009573:Nitrites; C558416:corvitin; D009569:Nitric Oxide; D008315:Malondialdehyde